Fenofibric acid - Takeda

Drug Profile

Fenofibric acid - Takeda

Alternative Names: Fibricor; MPC-028

Latest Information Update: 21 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator URL Pharma
  • Class Antihyperlipidaemics; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia

Most Recent Events

  • 21 May 2015 Fenofibric acid licensed to Tribute Pharmaceuticals in USA
  • 04 Jun 2012 URL Pharma has been acquired by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top